MedTrace Logo

Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience

NCT01083186 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2013-03-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.

Conditions

  • Chronic Kidney Failure
  • Secondary Hyperparathyroidism

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Christos Argyropoulos, MD · AbbVie Pharmaceuticals S.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01083186 on ClinicalTrials.gov